secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0000950170-23-008761
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio discontinues sickle cell gene therapy nula-cel, begins strategic review, reports FY2022 net loss $101.1M
--------------------------------------------------------------------------------

- Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.
- Initiated process to evaluate strategic alternatives; corporate restructuring to preserve capital while conducting review.
- FY2022 net loss $101.1M ($1.84/share); cash and equivalents $283.6M as of Dec 31, 2022.
- Voluntarily paused Phase 1/2 CEDAR study of nula-cel in Jan 2023 due to treatment-related pancytopenia.
- Intends to continue research on early-stage non-genotoxic conditioning program toward potential development candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/0000950170-23-008761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/grph-20230320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer